

## Newsletter

Lund 07 October 2021

# Scandinavian ChemoTech and its subsidiary Vetiquire has, in the wake of gradually lowered restrictions, taken the opportunity to show their potential at physical trade shows

*Scandinavian ChemoTech and Vetiquire has taken the opportunity to demonstrate the patented technology, Tumour Specific Electroporation (TSE), at physical trade shows as the restrictions now gradually are being lifted.*

### Animal Care

Vetiquire, sees a continuous great interest in the TSE technology from several veterinary clinics across northern Europe. As a lot of these clinics are familiar with the older static electroporation, the unique TSE technology is being acknowledged as the next generation with its dynamic feature designed not to damage healthy tissue. A feature that has been greatly appreciated by leading veterinarians.

Since launching the TSE technology to veterinarians several cats and dogs has been treated with promising results.

The feasibility study, which Vetiquire is conducting in the US, is progressing better than expected and has so far shown a true need for this new innovation on the North American market. The progress has been confirmed by our collaborative partner in the US whom is also happy to report that he can see a tremendous interest and curiosity pertaining TSE after our first conference in the US.

### Human Care

From the Oncology Convention in Birmingham can be reported that several visiting researchers within the field of electroporation got a true eyeopener when being introduced to our novel setting TSE in this field. Mohan Frick & Professor Bertil R Persson had the opportunity to give an appreciated lecture at the convention.

We also had some in-depth discussions with potential distributors who has shown great interest in distributing our technology.

*“After more than 18 months of pandemic barriers our marketing activities have been revived and we can once again visit our customers face to face. It feels really good to start the marketing and training, which after our CE-mark now also includes Europe and other countries acknowledging the certification.” – says Mohan Frick, CEO*

*For more information, please contact:*

Mohan Frick, CEO

+46 (0)10-218 93 00  
[info@chemotech.se](mailto:info@chemotech.se)

***Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)***

**Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se)